Genefron Ltd.

Genefron Ltd. is a company specializing in genomic expression-based personal diagnostics in viral and autoimmune diseases. It employs gene expression signatures derived from big data analysis, machine learning algorithms, and cell biology knowledge. The company has successfully developed its first three personal diagnostic kits (PDK), all of which have been CE marked and approved by the Israeli Ministry of Health. The IFR 300 kit is designed for Rheumatoid Arthritis (RA) patients and predicts the treatment outcome of the ‘Anti TNF’ drug family. It is being sold through Meuhedet HMO. The IFR 100 kit, aimed at Multiple Sclerosis (MS) patients, predicts the treatment outcome of the ‘Interferon β’ drug family. Finally, the IFR 200 kit predicts CMV (cytomegalovirus) transmission to the fetus in pregnant women and can be reimbursed by Clalit Mashlim. Founded in 2011 and based in Israel, Genefron has not disclosed its last investment details or investors. With its innovative approach to personalized medicine, the company holds significant potential for growth and impact in the field of healthcare.